Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive

// Hong Wang 1 , Ying Zhou 1 , Rong Yan 1 , Guo Qing Ru 2 , Li Li Yu 2 , Ming Shan Wang 1 and Mei Juan Chen 1 1 Department of Infectious Diseases, Zhejiang Provincial People’s Hospital, Zhejiang, People’s Hospital of Hangzhou Medical College, Zhejiang, China 2 Department of Pathology, Zhejiang Provincial People’s Hospital, Zhejiang, People’s Hospital of Hangzhou Medical College, Zhejiang, China Correspondence to: Hong Wang, email: hongwang71@yahoo.com Ying Zhou, email: zying918@126.com Keywords : E antigen positive; hepatitis B virus; liver fibrosis; liver biopsy; non-invasive fibrosis marker Received: May 09, 2017      Accepted: October 05, 2017      Published: October 24, 2017 ABSTRACT Background : Interest is growing in the use of non-invasive techniques for complementing liver biopsy for liver fibrosis assessment. We aimed to prospectively evaluate liver histology in chronic hepatitis B (CHB) patients with e-antigen positivity, and develop and validate a novel scoring system—e-antigen-positive CHB liver fibrosis (EPLF) score—for noninvasively predicting the fibrosis stages. Methods: We identified the baseline variables associated with fibrosis stage (MATAVIR score, F0–F4) in 212 CHB patients with e-antigen positivity. These significant variables were used to develop the EPLF scoring system. The EPLF score equation was developed based on the prediction of fibrosis stages via multivariate ordered logistic regression analysis. The diagnostic powers of the EPLF score and several non-invasive markers were assessed through an area under the receiver operating characteristic curve (AUROC) analyses. This EPLF score model was validated in another set of 208 similar patients. Results: The natural logarithms of serum albumin, HBeAg, and HBsAg levels were selected as significant independent variables for the EPLF score equation. The EPLF score had good diagnostic power (AUROC, 0.72–0.90, p<0.001) and good diagnostic accuracy (72–85%), with a high positive predictive value (80.8–92.8%) for each fibrosis stage in the test group. Similar results were observed in the validation group (AUROC, 0.73–0.89, p<0.001). The EPLF score exhibited a strong correlation with fibrosis stage (r=0.67, p<0.001), and was the preferable non-invasive marker for staging liver fibrosis. Conclusion: In e-antigen-positive patients with CHB, the EPLF score could serve as a potential non-invasive marker of liver fibrosis stage.